GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Lixisenatide (Adlyxin), adult single-ingredient SC injection

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Adlyxin - labeled renal guidance

Product / population
Lixisenatide (Adlyxin), adult single-ingredient SC injection
Renal method
Indexed GFR/eGFR, mL/min/1.73 m2
Source revision
Prescribing information revised 9/2023
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Adlyxin - product and source limitations

GI adverse effects can produce dehydration and worsen kidney function. Verify the single-ingredient pen and the dated source.

What to reconcile: Verify the current prescribing information for this presentation.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Adlyxin - labeled renal guidance

Open original reference

FDA / product prescribing information · Lixisenatide (Adlyxin), adult single-ingredient SC injection

Renal method: Indexed GFR/eGFR, mL/min/1.73 m2
Source date: Prescribing information revised 9/2023
Retrieved: 2026-11-07

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6

In mild or moderate impairment, no dose reduction is required; monitor renal function and adverse effects. Severe impairment (eGFR 15 to <30) has very limited experience and requires close monitoring. Use is not recommended in ESRD. GI adverse effects can produce dehydration and worsen kidney function. Verify the single-ingredient pen and the dated source.

RDM73-adlyxin-official-1 · Source locator: Renal guidance: 8.6

Source identity and provenance
Source family
product_label
Source
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208471s007lbl.pdf
Retrieved
2026-11-07
Renal-function method
Indexed GFR/eGFR, mL/min/1.73 m2
Source date/version
Prescribing information revised 9/2023
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
6b8d82ad958025ff19f22cbca6c5570c5f189f0f10b24548718bf14f90250a74

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=lixisenatide-adlyxin&s1=RDM73-adlyxin-official&h1=5f8aa01571ef179447ca3915776846315e47eed1e2878e68df7f3ec8b0202f52

Top